Joel Lexchin, University of British Columbia

Research

Adverse Drug Events Community-Based Primary Healthcare Drug Safety And Effectiveness Emergency Medicine Medication Review Planning Team Building Adverse Drug Event Reporting

Latest papers

Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature
Health Policy · 2020 · senior author
Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States.
The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2016
Pharmaceutical sales representatives and patient safety.
Journal of general internal medicine · 2013

All 6 publications

Latest funding

Safety Advisories Framework for Effective Risk communication - Phase 2 (SAFER-2)
CIHR · 2024 · Co-investigator
$753,524
What works best to protect public health? An international comparison of post-market regulatory risk communication on prescription drugs
CIHR · 2016 · Co-investigator
$1,158,976
When Treatments Harm: Building Better Systems and Enhancing Research Capacity to Reduce Adverse Drug Events
CIHR · 2015 · Co-investigator
$1,160,050

All 6 grants and awards

6 publications.

01

Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature

Morgan SG, Daw JR, Greyson D, Shnier A, Holbrook A, Lexchin J

Health Policy20202 citationsSenior author

DOI: 10.1016/j.healthpol.2019.12.010

02

Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States.

Habibi R, Guénette L, Lexchin J, Reynolds E, Wiktorowicz M, Mintzes B

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics2016

DOI: 10.1177/1073110516684803 PMID: 28661249

03

Pharmaceutical sales representatives and patient safety.

Mintzes B, Lexchin J, Wilkes MS, Beaulieu MD, Reynolds E, Sutherland J, Durrieu G

Journal of general internal medicine2013

DOI: 10.1007/s11606-013-2563-5 PMID: 23897129

04

Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States.

Mintzes B, Lexchin J, Sutherland JM, Beaulieu MD, Wilkes MS, Durrieu G, Reynolds E

Journal of general internal medicine2013

DOI: 10.1007/s11606-013-2411-7 PMID: 23558775

05

The cost of drug development: A systematic review

Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D

Health Policy2011448 citations

DOI: 10.1016/j.healthpol.2010.12.002

06

Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy.

Mintzes B, Barer M, Lexchin J, Bassett KL

Research in social & administrative pharmacy : RSAP2005

DOI: 10.1016/j.sapharm.2005.03.007 PMID: 17138480

Safety Advisories Framework for Effective Risk communication - Phase 2 (SAFER-2)

Co-investigatorCIHR2024Project Grant

Principal investigators: Dormuth, Colin R; Mintzes, Barbara J; Otte, Jessica

Keywords: Co-Design; Drug Utilization Research; Focus Groups; Knowledge Translation Exchange; Medication Safety; Quality Improvement; Risk Communication

$753,524

What works best to protect public health? An international comparison of post-market regulatory risk communication on prescription drugs

Co-investigatorCIHR2016Project Grant

Principal investigators: Dormuth, Colin R; Mintzes, Barbara J; Sketris, Ingrid S

Keywords: Drug Utilization Research; International Comparison; Key Informant Interviews; Medication Safety; Pharmacoepidemiology; Regulatory Policy; Risk Communication; Systematic Review

$1,158,976

When Treatments Harm: Building Better Systems and Enhancing Research Capacity to Reduce Adverse Drug Events

Co-investigatorCIHR2015Foundation Grant

Principal investigators: Hohl, Corinne M

Keywords: Adverse Drug Events; Clinical Decision Rule; Drug Safety And Effectiveness; Emergency Medicine; Internal Medicine; Patient Safety; Surveillance

$1,160,050

Adverse Drug Event Reporting in PharmaNet to Improve Patient Safety and Inform Policy

Principal investigatorCIHR2012Partnerships for Health System Improvement (PHSI)

Principal investigators: Hohl, Corinne M; Taylor, Amy; Balka, Ellen; Coleman, Jeff; Lexchin, Joel; Sobolev, Boris G

Keywords: Adverse Drug Event Reporting; Communication Across Healthcare Sectors; Drug Safety; Electronic Medical Records; Medication Information Systems; Pharmacosurveillance; Prevention

$596,000

Planning the Evaluation of Medication Review in Emergency Department Patients

Principal investigatorCIHR2012Planning Grants - Priority Announcement: Health Services and Policy Research

Principal investigators: Hohl, Corinne M; Lexchin, Joel; Sobolev, Boris G

Keywords: Adverse Drug Events; Community-Based Primary Healthcare; Drug Safety And Effectiveness; Emergency Medicine; Medication Review; Planning; Team Building

$24,997

Pharmaceutical Sales Representatives and Patient Safety: exploration of physician experiences in three countries and implications for regulatory policy

Principal investigatorCIHR2011Operating Grant

Principal investigators: Mintzes, Barbara J; Lexchin, Joel

Keywords: Comparison Of National Regulatory Policies; Cross-Sectional Survey; Drug Promotion; Family Practice; Focus Groups; Patient Safety; Pharmaceutical Policy; Policy Analysis

$247,925

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Frequent collaborators

Emergency Medicine
Anesthesiology, Pharmacology and Therapeutics
Medicine
School of Population and Public Health
Centre for Health Services and Policy Research
Centre for Global Health Research
Economics
Other

Co-authors at University of British Columbia, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.

Barbara Mintzes

Anesthesiology, Pharmacology and Therapeutics

4 shared papers, latest 2016

Jason Sutherland

Centre for Health Services and Policy Research

1 shared papers, latest 2013

Mary Wiktorowicz

Centre for Global Health Research

1 shared papers, latest 2016

Devon Greyson

School of Population and Public Health

1 shared papers, latest 2011

Paul Grootendorst

Economics

1 shared papers, latest 2011

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mention

Subject: Prospective PhD student: Adverse Drug Events Dear Professor Lexchin, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature" (2020), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Joel Lexchin

Research

Latest papers

Latest funding

Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature

Regulating Information or Allowing Deception? Pharmaceutical Sales Visits in Canada, France, and the United States.

Pharmaceutical sales representatives and patient safety.

Pharmaceutical sales representatives and patient safety: a comparative prospective study of information quality in Canada, France and the United States.

The cost of drug development: A systematic review

Introduction of direct-to-consumer advertising of prescription drugs in Canada: an opinion survey on regulatory policy.

Safety Advisories Framework for Effective Risk communication - Phase 2 (SAFER-2)

What works best to protect public health? An international comparison of post-market regulatory risk communication on prescription drugs

When Treatments Harm: Building Better Systems and Enhancing Research Capacity to Reduce Adverse Drug Events

Adverse Drug Event Reporting in PharmaNet to Improve Patient Safety and Inform Policy

Planning the Evaluation of Medication Review in Emergency Department Patients

Pharmaceutical Sales Representatives and Patient Safety: exploration of physician experiences in three countries and implications for regulatory policy

Frequent collaborators

Barbara Mintzes

Jason Sutherland

Morris Barer

Mary Wiktorowicz

Mary Wiktorowicz

Devon Greyson

Anne Marie Holbrook

Paul Grootendorst